Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Postpartum depression affects many new mothers, increasing suicide risk. New research shows preventive cognitive behavioral ...

Men experience and express depression differently, often coping through unhealthy behaviors and resisting treatment due to ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Using computational models, the researchers studied how the brain's reward-learning system functions in those with depression, especially among individuals experiencing anhedonia, the inability to ...

A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according t ...